GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Notes Receivable

Ocumension Therapeutics (HKSE:01477) Notes Receivable : HK$0.0 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Notes Receivable?

Ocumension Therapeutics's Notes Receivable for the quarter that ended in Dec. 2023 was HK$0.0 Mil.


Ocumension Therapeutics Notes Receivable Historical Data

The historical data trend for Ocumension Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Notes Receivable Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial - - - - -

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Ocumension Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Ocumension Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocumension Therapeutics (HKSE:01477) Business Description

Traded in Other Exchanges
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines